Objectives: This study aimed to evaluate the clinical efficacy of fertility-preserving therapy through in vitro fertilization (IVF) procedures in women who were pathologically diagnosed with endometrial hyperplasia or carcinoma.
Design: A retrospective cohort study on fertility-preserving therapy was conducted. Participants/Materials, Setting: A total of 82 women were enrolled who had simple endometrial hyperplasia (SH), complex hyperplasia (CH), complex atypical hyperplasia (CAH), and endometrioid endometrial carcinoma stage IA (EC IA) and underwent IVF at Gangnam CHA fertility center between January 2008 and December 2020.
Methods: The primary endpoints were oncologic outcomes and subsequent reproductive outcomes of patients who underwent fertility-preserving treatments analyzed by χ2 test or Fisher's exact test.
Results: Of the 82 patients, 33 had a cumulative clinical pregnancy (40.2%), and 25 had a cumulative live birth (30.5%) through IVF procedures following pathologic confirmation of complete remission or non-progressive status. The cumulative clinical pregnancy rates and live birth rates for SH were 50.0% and 30.0%, for CH were 37.8% and 28.9%, for CAH were 25.0% and 25.0%, and for EC were 38.5% and 38.5%, respectively. There were no significant differences in cumulative clinical pregnancy rates or live birth rates when comparing the four groups. There was a difference in endometrial thickness between medroxyprogesterone acetate (MPA) treatment group and intrauterine device (IUD) group (p = 0.036); however, there were no significant differences in clinical pregnancy rates among MPA, IUD, and MPA+IUD groups.
Limitations: Because of the retrospective nature of the study, many factors relevant to the treatment decision were not strictly controlled.
Conclusions: All endometrial hyperplasia and carcinoma groups had competent cumulative live birth rates by IVF procedures. There may be differences in endometrial thickness depending on the treatment methods, but this does not affect clinical pregnancy rates. Therefore, the fertility-preserving treatment for endometrial hyperplasia and carcinoma is a safe and feasible method that results in good IVF outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000539315 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of occult endometrial carcinoma in patients with endometrial intraepithelial neoplasia who underwent hysterectomy.
World J Surg Oncol
January 2025
Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
Objectives: To determine the prevalence of occult endometrial carcinoma in patients with endometrial intraepithelial neoplasia (EIN) post-hysterectomy and identify pre-hysterectomy risk factors predictive of occult carcinoma.
Methods: This retrospective study included patients diagnosed with EIN between 2007 and 2021 who underwent hysterectomy as primary treatment. An expert gynecologic pathologist reviewed pathological slides.
Fertility-sparing treatment outcomes using immune checkpoint inhibitors in endometrial cancer patients with Lynch syndrome.
J Gynecol Oncol
January 2025
Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Objective: To evaluate the efficacy of immune checkpoint inhibitors (ICIs) for fertility-sparing treatment in Lynch syndrome-associated endometrial cancer (LS-EC).
Methods: Four LS-EC cases received programmed cell death protein 1 (PD-1) inhibitors for fertility preservation at the Obstetrics and Gynecology Hospital of Fudan University from 2017 to 2023. The clinical data and long-term outcomes were retrospectively reviewed.
Predisposing Factors for Pseudoplacentational Endometrial Hyperplasia or Cystic Endometrial Hyperplasia in Dogs and Their Association with Pyometra.
Vet Sci
December 2024
Departamento de Clínica e Cirurgia Veterinária, Escola de Veterinária, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
Pseudoplacentational endometrial hyperplasia (PEH) and cystic endometrial hyperplasia (CEH) are both hyperplastic conditions that may occur in the canine uterus during diestrus. CEH can impair fertility, and, although the consequences of PEH are poorly known, this condition is significantly associated with pyometra. The aim of this study was to investigate frequencies of both PEH and CEH in female dogs according to age, size, breed, and breed group.
View Article and Find Full Text PDFHistopathology of incidental non-neoplastic findings in transgenic CByB6F1-Tg(HRAS)2Jic mice used in toxicity studies.
J Toxicol Pathol
January 2025
Labcorp Early Development Laboratories, Inc., 3635 Concorde Parkway, Suite 100, Chantilly, VA, 20151, USA.
This technical report presents a collection of illustrative images and concise descriptions of non-neoplastic microscopic findings noted in transgenic CByB6F1-Tg(HRAS)2Jic (Tg.rasH2) mice from 26-week-carcinogenicity studies. A unique finding in the Tg.
View Article and Find Full Text PDFCystic Spaces in the Endometrium on Ultrasound and Correlations With Pathological Diagnosis: A Contemporary Retrospective Cohort Study in a Tertiary Centre.
Aust N Z J Obstet Gynaecol
January 2025
Royal Women's Hospital, Melbourne, Victoria, Australia.
Objectives: To determine the correlation between the ultrasound finding of cystic spaces in the endometrium and endometrial hyperplasia or cancer.
Materials And Methods: We performed a retrospective cohort study at a tertiary teaching hospital in Victoria, Australia, between January 2014 and December 2016. Patients who had a tertiary ultrasound where the endometrium was assessed and underwent endometrial sampling in the subsequent year were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!